JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, H.
Right arrow Articles by Mehta, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, H.
Right arrow Articles by Mehta, J. L.

Vol. 294, Issue 2, 722-727, August 2000

Protection against Myocardial Dysfunction Induced by Global Ischemia-Reperfusion by Antisense-Oligodeoxynucleotides Directed at beta 1-Adrenoceptor mRNA1

Hongjiang Chen , Yuan Clare Zhang, Dayuan Li , M. Ian Phillips, Paullete Mehta, Min Shi and Jawahar L. Mehta

Departments of Medicine (H.C., D.L., M.S., J.L.M.), Physiology (Y.C.Z., M.I.P.), and Pediatrics (P.M.), University of Florida College of Medicine, and the Veterans Affairs Medical Center (H.C., D.L., M.S., J.L.M.), Gainesville, Florida

Plasma catecholamine levels rise, and myocardial beta 1-adrenoceptor (beta 1-AR) sensitivity increases during ischemia. These factors enhance myocardial injury and cardiac dysfunction. beta 1-AR blockers are clinically used to protect heart against ischemia and to improve cardiac dysfunction in patients with ischemic heart disease, but these agents often cause intolerable side effects. To examine the potential cardioprotective effect of therapy with antisense-oligodeoxynucleotides directed at beta 1-AR mRNA (beta 1-AS-ODNs) during myocardial ischemia-reperfusion, Sprague-Dawley rats were treated with beta 1-AS-ODNs or inverted-oligodeoxynucleotides (IN-ODNs), each 200 µg/rat. Hearts were excised, perfused, and subjected to global ischemia (30 min) followed by reperfusion (30 min). Other rats were given selective beta 1-AR blocker atenolol (2 mg/kg) or saline before excising the hearts. Ischemia-reperfusion resulted in cardiac dysfunction, indicated by an increase in coronary perfusion pressure and left ventricular end-diastolic pressure and a decrease in developed left ventricular pressure, as well as evidence of lipid peroxidation in saline-treated rats (all P < .05 versus control values). Administration of AS-ODNs or atenolol, but not IN-ODNs, protected hearts against functional deterioration and lipid peroxidation (P < .05 versus saline or IN-ODNs treatment). AS-ODNs therapy appeared to be equivalent to atenolol in these effects. Expression of beta 1-AR protein as well as mRNA in the myocardium were markedly up-regulated after ischemia-reperfusion, and treatment with beta 1-AS-ODNs, but not atenolol, decreased the rise in enhanced expression of beta 1-AR. These observations imply that beta 1-AS-ODNs can ameliorate cardiac dysfunction after ischemia-reperfusion by reducing the expression of beta 1-AR in the ischemic-reperfused myocardium.


1 This study was supported in part by a Merit Review Award from the Department of Veterans Affairs and a National Institutes of Health MERIT Award.


0022-3565/00/2942-0722$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
D. Kumar, V. Menon, W. R. Ford, A. S. Clanachan, and B. I. Jugdutt
Effect of Angiotensin II lype 2 Receptor Blockade on Activation of Mitogen-Activated Protein Kinases after Ischemia-Reperfusion in Isolated Working Rat Hearts
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 285 - 296.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. Verma, A. Maitland, R. D. Weisel, P. W. M. Fedak, N. C. Pomroy, S.-H. Li, D. A. G. Mickle, R.-K. Li, and V. Rao
Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation
J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1074 - 1083.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xu, D. Kumar, J. R. B. Dyck, W. R. Ford, A. S. Clanachan, G. D. Lopaschuk, and B. I. Jugdutt
AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts
Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1206 - H1215.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Tang, M. Jackson, K. Qian, and M. I. Phillips
Hypoxia Inducible Double Plasmid System for Myocardial Ischemia Gene Therapy
Hypertension, February 1, 2002; 39(2): 695 - 698.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.